The role of emerging therapies in the treatment of benign prostatic hyperplasia. Is it any place?

Ioannis Glykas, Ioannis Gkialas

Abstract


Benign prostatic hyperplasia (BPH) may lead to bladder outflow obstruction and symptoms in older men The latest developments as far as it concerns surgical treatment are focused on two principles: an office  based  procedure  without  the  need  for  general  anesthesia; and minimizing incontinence and sexual dysfunction  related  side  effects  while  retaining  satisfactory clinical efficacy. The aim of this review is to evaluate evolving minimally invasive therapies for the treatment of lower urinary tract symptoms (LUTS) caused by BPH in which ongoing clinical trials show early promise, namely, intra-prostatic injections, alcohol ablation, aquablation, the Rezum device, prostatic artery embolization (PAE), and histotripsy.


Keywords


benign prostatic hyperplasia; alcohol ablation; aquablation, Rezum; histotripsy; embolization

Full Text:

PDF

References


Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50(6): 1306-1314.

Lee SW, Choi JB, Lee KS, et al. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: A quality and meta-analysis. Int Neurourol J 2013;17(2): 59-66.

Lusuardi L, Hruby S, Janetschek G. New emerging technologies in benign prostatic hyperplasia. Curr Opin Urol 2013;23(1): 25-29.

Chung A, Woo HH. What’s truly minimally invasive in benign prostatic hyperplasia surgery? Curr Opin Urol 2014;24(1): 36-41.

Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: An update for clinicians. Ther Adv Chronic Dis 2011;2(6): 377-383.

Elhilali MM, Pommerville P, Yocum RC, et al. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 2013;189(4): 1421-1426.

Kunit T, Lusuardi L. An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol 2014;6: 67-70.

Shore N. NX-1207: A novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2010;19(2): 305-310.

Denmeade SR, Egerdie B, Steinhoff G, et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59(5): 747-754.

Sakr M, Eid A, Shoukry M, Fayed A. Transurethral ethanol injection therapy of benign prostatic hyperplasia: Four year follow up. Int J Urol 2009;16(2): 196-201.

El-Husseiny T, Buchholz N. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: Long-term follow-up. J Endourol 2011;25(3): 477-480.

Plante MK, Marks LS, Anderson R, et al. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007;177(3): 1030-1035.

Goya N, Ishikawa N, Ito F, et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: Preliminary report on application of a new technique. J Urol1999 ;162(2): 383-386.

Gilling P, Tan A, Anderson P. PD5-02 Multicenter experience of a novel treatment for BPH: Aquablation image guided robot-assisted water jet ablation of the prostate. J Urol 2015;193(4): e92-e93.

Faber K, de Abreu AL, Ramos P, et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: Initial study of a novel technology for benign prostatic hyperplasia. J Endourol 2015;29(1): 63-69.

Dixon C, Cedeno ER, Pacik D, et al. PD26-09 transurethral water vapor therapy for BPH; 1-year clinical results of the first-in-man and Rezum I clinical trials using the Rezum system. J Urol 2014;4(191): e762.

Mynderse LA, Hanson D, Robb RA, et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: Validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 2015;86(1): 122-127.

Somani BK, Hacking N, Bryant T, et al. Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH). BJU Int 2014;114(5): 639-640.

Schreuder SM, Scholtens AE, Reekers JA, et al. The role of prostatic arterial embolization in patients with benign prostatic hyperplasia: A systematic review. Cardiovasc Intervent Radiol 2014;37(5): 1198-1219.

Wang MQ, Guo LP, Zhang GD, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (> 80 mL) benign prostatic hyperplasia: Results of midterm follow-up from Chinese population. BMC Urol 2015;15(1): 33.

Carnevale FC, Antunes AA, Da Motta-Leal-Filho JM, et al. Review of current outcomes of prostate artery embolization to treat patients with lower urinary tract symptoms due to benign prostatic hyperplasia. UroToday International Journal 2012; 5(5): 1-6.

Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, et al. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol 2013;24(4): 535-542.

Pisco JM, Tinto HR, Campos Pinheiro L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short-and mid-term follow-up. Eur Radiol, 2013;23(9): 2561-2572.

Tinto HR, Pisco JM, Bilhim T, et al. Prostatic artery embolization in the treatment of benign prostatic hyperplasia: Short and medium follow-up. Tech Vasc Interv Radiol 2012;15(4): 290-293.

Grosso M, Balderi A, Arno M, et al. Prostatic artery embolization in benign prostatic hyperplasia: Preliminary results in 13 patients. Radiol Med 2015;120(4): 361-368.

Antunes AA, Carnevale FC, da Motta Leal Filho JM, et al. Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. J Vasc Interv Radiol, 2013;36(4): 978-986.

Clinical Trials.gov. UK Rope Register Study. Available from URL: https://clinicaltrials.gov/ct2/show/NCT02434575. Accessed 14th June 2015.

Lake AM, Hall TL, Kieran K, et al. Histotripsy: Minimally invasive technology for prostatic tissue ablation in an in vivo canine model. Urology 2008;72(3): 682-686.

Roberts WW. Development and translation of histotripsy: Current status and future directions. Curr Opin Urol,2014;24(1):104.

Wheat JC, Hall TL, Hempel CR et al. Prostate histotripsy in an anticoagulated model. Urology 2009;75(1): 207-211.

Hall TL, Hempel CR, Lake AM, et al. Histotripsy for the treatment of BPH: Evaluation in a chronic canine model. Ultrason Symp 2008; 765-767.

Allam CL, Wilkinson JE, Cheng X, et al. Histotripsy effects on the bladder trigone: functional and histologic consequences in the canine model. J Endourol 2009;27(10): 1267-1271.

Styn N, Hall TL, Fowlkes JB, et al. Histotripsy homogenization of the prostate: Thresholds for cavitation damage of periprostatic structures. J Endourol 2011;25(9):1.

Hempel CR, Hall TL, Cain CA, et al. Histotripsy fractionation of prostate tissue: Local effects and systemic response in a canine model. J Urol 2011;185(4): 1484-1489.

Clinical Trials.gov. Safety and initial efficacy study of the Vortx Rx for treatment of benign prostatic hyperplasia (Canada). Available from URL: https://clinicaltrials.gov/ct2/show/NCT01775488. Accessed 14th June, 2015.




DOI: http://dx.doi.org/10.19264/hj.v29i3.197